Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

npj Vaccines

Volumn 2, Issue 1, 2017, Pages

  Lutz, Johannes ^a   Lazzaro, Sandra ^a   Habbeddine, Mohamed ^a   Schmidt, Kim Ellen ^a   Baumhof, Patrick ^a   Mui, Barbara L ^b   Tam, Ying K ^b   Madden, Thomas D ^b   Hope, Michael J ^b   Heidenreich, Regina ^a   Fotin Mleczek, Mariola ^a  

^a CureVac GmbH   (Germany)

^b Acuitas Therapeutics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042232690     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/s41541-017-0032-6     Document Type: Article

References (35)

1. Hoerr, I., Obst, R., Rammensee, H. G. & Jung, G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30, 1-7 (2000).
2. Kallen, K.-J. et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum. Vaccines Immunother. 9, 2263-2276 (2013).
3. Sullenger, B. A. & Nair, S. From the RNA world to the clinic. Science 352, 1417-1420 (2016).
4. Ulmer, J. B. & Geall, A. J. Recent innovations in mRNA vaccines. Curr. Opin. Immunol. 41, 18-22 (2016).
5. Nabel, G. J. Designing tomorrow's vaccines. N. Engl. J. Med 368, 551-560 (2013).
6. Koff, W. C. et al. Accelerating next-generation vaccine development for global disease prevention. Science 340, 1232910 (2013).
7. Schnee, M. et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis. 10, e0004746 (2016).
8. Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210-1216 (2012).
9. Fotin-Mleczek, M. et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34, 1-15 (2011).
10. Geall, A. J. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 109, 14604-14609 (2012).
11. Brito, L. A. et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. J. Am. Soc. Gene Ther. 22, 2118-2129 (2014).
12. Richner, J. M. et al. Modified mRNA vaccines protect against zika virus infection. Cell. https://doi.org/10.1016/j.cell.2017.02.017 (2017).
13. Richner, J. M. et al. Vaccine mediated protection against zika virus-induced congenital disease. Cell 170, 273-283.e12 (2017).
14. Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature https://doi.org/10.1038/nature21428 (2017).
15. Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 Influenza Viruses. Mol. Ther. J. Am. Soc. Gene Ther. 25, 1316-1327 (2017).
16. Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. J. Am. Soc. Gene Ther. 23, 1456-1464 (2015).
17. Reichmuth, A. M., Oberli, M. A., Jeklenec, A., Langer, R. & Blankschtein, D. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 7, 319-334 (2016).
18. Platt, A. & Wetzler, L. Innate immunity and vaccines. Curr. Top. Med. Chem. 13, 2597-2608 (2013).
19. Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control Release 217, 345-351 (2015).
20. Groom, J. R. & Luster, A. D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207-215 (2011).
21. Plotkin, S. A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401-409 (2008).
22. Novartis Vaccines and Diagnostics GmbH & Co. KG. Package leaflet RABIPUR®. (2006).
23. Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247-258 (2008).
24. Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M. & Lugli, E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur. J. Immunol. 43, 2797-2809 (2013).
25. Karikó, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165-175 (2005).
26. Andries, O. et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Release 217, 337-344 (2015).
27. Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51, 8529-8533 (2012).
28. Stevenson, F. K., Ottensmeier, C. H. & Rice, J. DNA vaccines against cancer come of age. Curr. Opin. Immunol. 22, 264-270 (2010).
29. Lopez-Gordo, E., Podgorski, I. I., Downes, N. & Alemany, R. Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Hum. Gene Ther. 25, 285-300 (2014).
30. Coelho, T. et al. Safety and efficacy of rnai therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819-829 (2013).
31. Bogers, W. M. et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying rna vaccine expressing hiv type 1 envelope with a cationic nanoemulsion. J. Infect. Dis. 211, 947-955 (2015).
32. Pascolo, S. Vaccination with messenger RNA. Methods Mol. Med. 127, 23-40 (2006).
33. Pascolo, S. Vaccination with messengerRNA (mRNA). Handb. Exp. Pharmacol. https://doi.org/10.1007/978-3-540-72167-3-11 (2008).
34. Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. J. Am. Soc. Gene Ther. 21, 1570-1578 (2013).
35. Kowalczyk, A. et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine 34, 3882-3893 (2016).